glp 1 agonist news Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists GLP-1 Receptor Agonists and vision

Analysts see US focused alcohol companies facing the most exposure from increased obesity medicine usage and expect a roughly 2% drop in consumption by 2035. As for GLP-1 drug users, survey data from the Brightfield Group suggests that a substantial portion are city dwellers with higher incomes that are actively engaged in exercise and diet management, while a recent survey of 2,000 US consumers from direct-to-consumer company Daily Harvest found that GLP-1 drugs were more appealing to those with self-described very healthy diets

Newswise Researchers at Washington University School of Medicine in St

Hirasawa N, Shimizu Y, Haginoya A, Soma Y, Watanabe G, Takehara K, et al

Data Availability No additional data are available

As obesity is a complex, chronic and progressive disease, it requires also an individualised and adaptive over time approach [14, 102]

Furman, B